Abstract
The completion of the human genome sequencing project and the establishment of new methods for the detection of point mutations have lead to a remarkable increase of sequence variants identification in a growing number of genes. As a result of this, a new field of research has emerged, pharmacogenomics, which deals with the influence of genetic variation on drug response by correlating gene expression or single-nucleotide polymorphisms with a drugs efficacy or toxicity. Genetic databases are continuously updated online repositories of mutation data, described for a single or more genes or specifically for a population or ethnic group. Genetic databases can also fulfil the mission of pharmacogenomics by helping elucidate gene function, estimate the prevalence of genes in populations, differentiate among subtypes of diseases, trace how genes may predispose to or protect against illnesses, and improve medical intervention. Therefore, it is expected that genetic databases will gradually assume an increasing importance in all aspects of genome medicine. This article aims to provide an update of the current and emerging types of genetic databases relevant to the field of pharmacogenomics. Moreover, the key elements that are holding back the field as well as the challenges that should be addressed in the near future are also commented.
Keywords: Databases, mutations, pharmacogenetics, pharmacogenomics
Current Pharmaceutical Design
Title: Genetic Databases and their Potential in Pharmacogenomics
Volume: 16 Issue: 20
Author(s): George Lagoumintzis, Konstantinos Poulas and George P. Patrinos
Affiliation:
Keywords: Databases, mutations, pharmacogenetics, pharmacogenomics
Abstract: The completion of the human genome sequencing project and the establishment of new methods for the detection of point mutations have lead to a remarkable increase of sequence variants identification in a growing number of genes. As a result of this, a new field of research has emerged, pharmacogenomics, which deals with the influence of genetic variation on drug response by correlating gene expression or single-nucleotide polymorphisms with a drugs efficacy or toxicity. Genetic databases are continuously updated online repositories of mutation data, described for a single or more genes or specifically for a population or ethnic group. Genetic databases can also fulfil the mission of pharmacogenomics by helping elucidate gene function, estimate the prevalence of genes in populations, differentiate among subtypes of diseases, trace how genes may predispose to or protect against illnesses, and improve medical intervention. Therefore, it is expected that genetic databases will gradually assume an increasing importance in all aspects of genome medicine. This article aims to provide an update of the current and emerging types of genetic databases relevant to the field of pharmacogenomics. Moreover, the key elements that are holding back the field as well as the challenges that should be addressed in the near future are also commented.
Export Options
About this article
Cite this article as:
Lagoumintzis George, Poulas Konstantinos and P. Patrinos George, Genetic Databases and their Potential in Pharmacogenomics, Current Pharmaceutical Design 2010; 16 (20) . https://dx.doi.org/10.2174/138161210791792804
DOI https://dx.doi.org/10.2174/138161210791792804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Editorial (Development and Routine Production of 11C- and 18F-Labelled Radiopharmaceuticals for Positron Emission Tomography)
Current Organic Chemistry Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets All for Statins and Statins for All; An Update
Current Pharmaceutical Design Multiplexed Fluorescence Imaging of Tumor Biomarkers in Gene Expression and Protein Levels for Personalized and Predictive Medicine
Current Molecular Medicine Neoadjuvant Therapy for HER2-positive Breast Cancer
Reviews on Recent Clinical Trials In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging A Systematic Evaluation of Solubility Enhancing Excipients to Enable the Generation of Permeability Data for Poorly Soluble Compounds in Caco-2 Model
Drug Metabolism Letters Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions
Current Molecular Pharmacology Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress
Current Pharmaceutical Design